PepStackPepStack
Back to Peptide Library

Cerebrolysin

Cerebrolysin (porcine brain-derived peptide preparation; FPF-1070)

Late-Stage ClinicalInvestigationalMixed / Secondary ResultsPorcine Brain-Derived Peptide Extract

Clinical trials showed mixed results. Benefits were seen on some measures but not others.

An injectable medication derived from pig brain tissue that provides brain cell-nourishing support, used clinically in over 40 countries for stroke recovery, traumatic brain injury, and dementia. It has not been approved by the US FDA or European EMA, but is widely used in Europe, Asia, and Russia.

Neurological HealthInjury & Recovery
12 studiesReviewed 2026-03-12Intravenous (IV) -- primary clinical route; up to 10 mL slowly over ~3 min undiluted, or 10-50 mL diluted in ≥100 mL saline infused over 15-60 min · Intramuscular (IM) -- up to 5 mL per injection undiluted, injected slowly over ~3 min

This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.

Safety Summary

Overall safety profile is favorable. Acute adverse events are generally mild, transient, and occur at rates comparable to placebo in randomized trials. Slow administration recommended to reduce flushing/palpitations risk. No preclinical or clinical evidence of carcinogenicity or oncogenic signaling. However, a Cochrane review (PMC6478305) noted a potential excess of non-fatal SAEs in the cerebrolysin group in pooled acute stroke analyses. Long-term/chronic use safety data are limited but available observational data do not suggest cumulative toxicity; PMC7387239.

Clinical check-in

If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.

Sources: [1-12]